Phase II Study of LBL-024 Combination Therapy for Adults With Advanced Solid Tumors Including NSCLC

What this Trial Is About

Researchers are evaluating the combination of LBL-024 with other drugs for treating patients with advanced non-small cell lung cancer NSCLC in this open-label, multicenter phase II clinical trial. The study aims to assess the efficacy and safety of LBL-024 combined with various chemotherapy drugs. It plans to enroll up to 230 participants who have advanced solid tumors and measurable lesions. The trial consists of four cohorts, each including a safety run-in period where a small group receives LBL-024 combined with different drugs such as docetaxel, bevacizumab, pemetrexed, carboplatin, and paclitaxel through intravenous infusion. After a 21-day safety observation, researchers evaluate tolerability before continuing enrollment and extension treatments. Some cohorts include maintenance treatment phases with LBL-024 alone or combined with other drugs. Participants will undergo treatment and follow-up visits to monitor response and safety. Researchers will assess outcomes including objective response rate, disease control rate, duration of response, drug concentration levels, and immunogenicity. The study involves regular laboratory tests, physical assessments, and evaluation of measurable tumor lesions. Participation lasts through the treatment and a 28-day follow-up after stopping the study drug or before new anti-tumor therapy starts.

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]